RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Two new series of cannabinoids were prepared and their affinities for the CB1 and CB2 receptors were determined. These series are the (2'R)- and (2'S)-1-methoxy- and 1-deoxy-3-(2'-methylalkyl)-Delta(8)-tetrahydrocannabinols, with alkyl side chains of three to seven carbon atoms. These compounds were prepared by a route that employed the enantioselective synthesis of the resorcinol precursors to the cannabinoid ring system. All of these compounds have greater affinity for the CB2 receptor than the CB1 receptor and four or them, (2'R)-1-methoxy-3-(2'-methylbutyl)-Delta(8)-THC (JWH-359), (2'S)-1-deoxy-3-(2'-methylbutyl)-Delta(8)-THC (JWH-352), (2',S)-1-deoxy-3-(2'-methylpentyl)-Delta(8)-THC (JWH-255), and (2'R)-1-deoxy-3-(2'-methylpentyl)-Delta(8)-THC (JWH-255). have good affinity (K-i = 13-47 nM) for the CB2 receptor and little affinity (K-i = 1493 to > 10,000 nM) for the CB1 receptor. In the 1-deoxy-3-(2'-methylalkyl)-Delta(8)-THC series, the 2'S-methyl compounds in general have greater affinity for the CB2 receptor than the corresponding 2'R isomers. (c) 2005 Elsevier Ltd. All rights reserved